Skip to content

Clinical study of Heyan Kuntai capsule in the treatment of ovarian hypofunction

Efficacy and safety of Heyan Kuntai capsule in the treatment of ovarian hypofunction: prospective, self controlled clinical study

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPB-17013916
Enrollment
Unknown
Registered
2017-12-14
Start date
2018-02-28
Completion date
Unknown
Last updated
2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diminished ovary function

Interventions

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) pregnant women of 25-40 years of age who wished to conceive naturally; (2) meet the diagnostic criteria of ovarian hypofunction; (3) informed consent, voluntary test.

Exclusion criteria

Exclusion criteria: (1) patients with premature ovarian failure (FSH > 40 IU/L); (2) endometriosis, adenomyosis, endometrial lesions (submucous myoma, endometrial polyps), uterine fibroids > 4 cm; (3) polycystic ovary syndrome, hyperprolactinemia, Kaohsiung hormone, hypothyroidism, adrenal dysfunction and other endocrine diseases affect ovulation; (4) genetic factors, tubal factors, congenital physiological defects or malformations, dysplasia caused by abnormal ovarian function in infertile patients, and male reproductive dysfunction infertility patients; (5) allergic to the study of prescriptions; (6) combined with cardiovascular, hepatic, renal, hematopoietic and other serious primary diseases, mental patients; (7) patients who are participating in other clinical trials or have participated in other clinical trials in the past month; (8) patients who are unfit for medication according to the instructions; (9) the researchers identified other patients who were not eligible for the study.

Design outcomes

Primary

MeasureTime frame
Anti-Mullerian Hormone; AMH;Antral Follicle Count, AFC;

Secondary

MeasureTime frame
FSH;E2;LH;P;T;pregnancy rate;

Countries

China

Contacts

Public ContactShixuan Wang

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

sxwang@tjh.tjmu.edu.cn+86 027-83662688

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026